What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Slides:

Advertisements

Similar presentations

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.

Advertisements

Audeh MW et al. ASCO 2009; Abstract (Clinical Science Symposium)

Dr Tracie Miles % of women with OC will have a BRCA gene mutation (Zhang et al 2011) Women with this gene mutation often have more aggressive, fast-growing.

Clinical and Research Updates in Gynecologic Oncology

Case Discussion: Second Opinion

Triple-Negative and BRCA-Mutated Metastatic Breast Cancer

Ovarian cancer update Kentucky cancer Registry 9/8/2016

Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

State of the Art in BRCA-Mutated Ovarian Cancer

Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

The Use of PARP Inhibitors in Breast Cancer: Challenges and Opportunities.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

An Introduction to DNA Damage Repair in Cancer: Beyond PARP

Steps to Optimizing Outcomes in Patients With Advanced Prostate Cancer

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Perspectives on Triple-Negative Breast Cancer

PARP Inhibition: The New Frontier in Recurrent Ovarian Cancer

BRCA, HRR Deficiency, and PARP Inhibitors

The Nurse View.

MOCA Living Well: Understanding PARP Inhibitors in Ovarian Cancer

PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

Cost Effectiveness and Optimal Outcomes in HF

PARP Inhibitors and Cancer: What Do You Need to Know?

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

Tailoring Hemophilia Prophylaxis Therapy

Counseling Patients About Germline BRCA Mutations

EGFR Inhibitors in Advanced NSCLC: Who, When, and Why?

Managing gBRCA-Positive Metastatic Breast Cancer

Management Challenges in CLL

Individualizing Care in Ovarian Cancer

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

Overview. Maximizing the Safety of CAR T-Cell Therapy: Prevention, Early Recognition, and Management.

GEMSTONE Educational Case Summary

Real-World Evidence in VTE

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

PARP Inhibitors and Ovarian Cancer: What Did Data From Washington, DC, Tell Us?

Maintenance Therapy in Advanced Ovarian Cancer

The Road to Quality Improvement in HER2-Positive Breast Cancer

PARP Inhibitors.

Molecular Testing in Ovarian Cancer: Is the Time Now?

The Changing Field of Melanoma: Ipilimumab.

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Practical Guidance on the Management of Pan-Negative NSCLC

(A) Safety profile overview.

MAINTENANCE THERAPY WITH PARP INHIBITORS

EVOLUTION OF PARP INHIBITORS IN OVARIAN CANCER

Preparing for Checkpoint Inhibitors in Breast Cancer

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Educational Objectives

Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Volume 147, Issue 3, Pages (December 2017)

Checkpoint Inhibitors in First-Line Advanced NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Moving Care Forward in Advanced Gastric Cancer

Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

HBOC Genetic counseling: major concerns and communication skills

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Clinical Focus.

Identifying TRK Fusions in Head and Neck Cancer

The Nurse View.

Changes in tumor sizes, CA-125, serum ceruloplasmin, and copper levels in 5 patients with platinum-resistant high-grade epithelial ovarian cancer who received.

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Uncovering the Right Sequence

Optimizing Patient Outcomes in Metastatic Triple-Negative Breast Cancer.

Presentation transcript:

What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer

Program Goals

Ovarian Cancer Overview

PARP Inhibition in Ovarian Cancer

Testing for BRCA1/2 Mutations

PARP Inhibitors Under Development

Olaparib in Patients With BRCA1/BRCA2 Ovarian Cancer

PARP Inhibitors in Patients With BRCA1/BRCA2 Ovarian Cancer

PARP Inhibitors as Maintenance Therapy

Biomarkers to Measure PARP Inhibitor Response

PARP Inhibitors and Chemotherapy

Olaparib Maintenance Therapy

Velaparib in Patients With Recurrent Disease

Major Toxicities of PARP Inhibitors

Outstanding Questions

Abbreviations

References

References (cont)

References (cont)

References (cont)